GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shanghai Pharmaceuticals Holding Co 601607.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

16.54

-1.31%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥283.58bn

FY2016FY2025

Net income

CN¥5.72bn

FY2016FY2025

Free cash flow

CN¥3.83bn

FY2016FY2025

Shareholders' equity

CN¥75.89bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥283.58bnCN¥275.25bnCN¥260.30bnCN¥231.98bnCN¥215.82bnCN¥191.91bnCN¥186.57bnCN¥159.08bnCN¥130.85bnCN¥120.76bn
Gross profitCN¥30.42bnCN¥30.41bnCN¥30.93bnCN¥30.38bnCN¥28.41bnCN¥26.24bnCN¥26.46bnCN¥22.11bnCN¥16.58bnCN¥14.11bn
Research and developmentCN¥2.34bnCN¥2.39bnCN¥2.20bnCN¥2.11bnCN¥1.99bnCN¥1.66bnCN¥1.35bnCN¥1.06bnCN¥790.3mCN¥670.5m
Operating incomeCN¥11.16bnCN¥8.14bnCN¥7.67bnCN¥9.01bnCN¥8.21bnCN¥7.18bnCN¥7.46bnCN¥6.31bnCN¥5.23bnCN¥4.95bn
Net incomeCN¥5.72bnCN¥4.55bnCN¥3.77bnCN¥5.62bnCN¥5.09bnCN¥4.50bnCN¥4.08bnCN¥3.88bnCN¥3.52bnCN¥3.20bn
Diluted earnings per share1.541.231.021.521.791.591.441.371.311.19

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥233.15bnCN¥221.21bnCN¥211.97bnCN¥198.13bnCN¥163.44bnCN¥149.19bnCN¥137.03bnCN¥126.88bnCN¥94.34bnCN¥82.74bn
Cash and short-term investments—CN¥44.38bnCN¥40.67bnCN¥37.01bnCN¥22.39bnCN¥22.30bnCN¥18.15bnCN¥18.69bnCN¥14.84bnCN¥11.97bn
Total liabilitiesCN¥143.36bnCN¥137.47bnCN¥131.65bnCN¥120.13bnCN¥104.37bnCN¥94.44bnCN¥87.64bnCN¥80.45bnCN¥54.67bnCN¥45.91bn
Debt—CN¥65.85bnCN¥61.87bnCN¥50.51bnCN¥45.46bnCN¥41.59bnCN¥39.67bnCN¥35.16bnCN¥20.68bnCN¥16.18bn
Shareholders' equityCN¥75.89bnCN¥71.68bnCN¥68.52bnCN¥67.06bnCN¥49.36bnCN¥45.35bnCN¥41.66bnCN¥39.01bnCN¥34.03bnCN¥31.62bn
Shares outstanding3,708m3,705m3,703m3,698m2,843m2,827m2,842m2,825m2,689m2,689m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥6.15bnCN¥5.83bnCN¥5.23bnCN¥4.74bnCN¥5.06bnCN¥6.84bnCN¥6.02bnCN¥3.14bnCN¥2.65bnCN¥1.95bn
Capital spending−CN¥2.33bn−CN¥2.40bn−CN¥2.97bn−CN¥2.68bn−CN¥4.12bn−CN¥3.01bn−CN¥2.75bn−CN¥1.94bn−CN¥2.01bn−CN¥2.12bn
Free cash flowCN¥3.83bnCN¥3.43bnCN¥2.26bnCN¥2.06bnCN¥942.6mCN¥3.83bnCN¥3.27bnCN¥1.19bnCN¥641.5m−CN¥172.6m
Dividends paid−CN¥2.80bn−CN¥3.60bn−CN¥3.98bn−CN¥1.55bn−CN¥1.36bn−CN¥1.25bn−CN¥1.17bn−CN¥2.36bn−CN¥1.75bn−CN¥1.44bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥72.21bnCN¥75.26bnCN¥68.51bnCN¥73.48bnCN¥70.83bnCN¥70.76bnCN¥65.62bnCN¥70.22bn
Gross profitCN¥8.17bnCN¥8.09bnCN¥8.00bnCN¥7.49bnCN¥7.68bnCN¥7.26bnCN¥7.24bnCN¥7.10bn
Operating incomeCN¥2.96bnCN¥2.90bnCN¥2.06bnCN¥1.47bnCN¥4.69bnCN¥2.28bnCN¥1.47bnCN¥1.84bn
Net incomeCN¥2.09bnCN¥1.42bnCN¥577.5mCN¥688.2mCN¥3.13bnCN¥1.33bnCN¥498.4mCN¥1.11bn
Diluted earnings per share0.560.380.160.190.840.360.130.30
Cash from operations———CN¥1.56bnCN¥3.19bn−CN¥2.17bnCN¥3.42bnCN¥2.54bn
Capital spending−CN¥353.0m−CN¥687.0m−CN¥713.0m−CN¥487.0m−CN¥394.0m−CN¥729.0m−CN¥565.0m−CN¥442.0m
Free cash flow———CN¥1.07bnCN¥2.80bn−CN¥2.89bnCN¥2.85bnCN¥2.10bn
Total assetsCN¥240.77bnCN¥235.37bnCN¥233.15bnCN¥236.75bnCN¥238.07bnCN¥225.87bnCN¥221.21bnCN¥223.74bn
Cash and short-term investments———CN¥44.55bnCN¥47.50bnCN¥45.03bnCN¥44.38bnCN¥42.39bn
DebtCN¥3.28bnCN¥3.26bnCN¥4.24bnCN¥56.28bnCN¥50.32bnCN¥49.53bnCN¥46.40bnCN¥46.50bn
Shareholders' equityCN¥78.35bnCN¥77.30bnCN¥75.89bnCN¥75.78bnCN¥75.10bnCN¥73.01bnCN¥71.68bnCN¥70.87bn

Financial ratios

Data as of 15 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin10.7%11.0%11.9%13.1%13.2%13.7%
Operating margin3.9%3.0%2.9%3.9%3.8%3.7%
Net margin2.0%1.7%1.4%2.4%2.4%2.3%
Return on equity7.5%6.4%5.5%8.4%10.3%9.9%
Return on assets2.5%2.1%1.8%2.8%3.1%3.0%
Free cash flow yield14.0%13.6%13.6%12.3%19.8%21.4%
Revenue growth3.0%5.7%12.2%7.5%12.5%2.9%
Earnings growth25.7%20.8%-32.9%10.3%13.3%10.2%
Current ratio1.33x1.36x1.33x1.35x1.27x1.22x
Debt to equity0.06x0.65x0.60x0.51x0.87x0.87x
Equity ratio32.6%32.4%32.3%33.8%30.2%30.4%
Interest coverage6.62x4.10x4.61x5.08x5.15x4.83x
R&D as a share of sales0.8%0.9%0.8%0.9%0.9%0.9%
Buybacks as a share of market value-0.1%-0.0%-0.2%-30.0%-0.6%0.5%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue6.9%8.1%10.4%
Operating income7.4%9.2%11.7%
Net income0.6%4.9%7.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin10.9%11.6%12.1%12.4%
Operating margin3.5%3.4%3.5%3.7%
Net margin1.8%1.9%2.0%2.2%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings11.617.116.411.711.112.112.812.418.516.5
Price to sales0.20.30.20.30.30.30.30.30.50.4

Dividends and splits

Per share, in the currency the company pays

Paid for 18 years. Last went ex-dividend on 5 Jan 2026.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year0.410.490.610.420.480.440.410.38
  • 6-for-5 split · 16 Aug 2007
  • 3-for-2 split · 19 Jun 2003
  • 1.17-for-1 split · 15 May 2001
  • 3-for-2 split · 6 May 1999
  • 3-for-2 split · 9 Jun 1997

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.